Clinical Trials
Oscient Pharmaceuticals completes enrollment in Phase IV trial of Factive
Published in Medical Letter on the CDC and FDA, February 25th, 2007
Known as the FORCE trial (FACTIVE Outpatient Respiratory Infection Community Experience), Oscient began enrollment coincident with the launch of Factive in the fall of 2004. A commitment to complete post-marketing trials has become a condition of approval for many drugs and this trial was expected to take three to four years to complete. Patient enrollment at more than 200 clinical sites was completed nearly one year ahead of schedule, which allows for the submission of the study report to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Neurourology
Studies from University of California, Department of Urology yield new data on neurourology - Accreditation
Humana Military Healthcare Services receives URAC HIPAA Privacy Accreditation - Addiction Medicine
Ortho-Clinical Diagnostics offers complete drugs-of-abuse panel, adds five assays - Business Update
Aethlon Medical signs government research alliance - Business Update
CytoCore ready to manufacture e2 Collector - Business Update
Generic Medical Devices receives 510(k) clearance for GMD Universal Circumcision Clamp - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
